Evidence map›Paper›PMID 37511593›Full record

ArticleInternational journal of molecular sciences2023

Investigation of Clinically Significant Molecular Aberrations in Patients with Prostate Cancer: Implications for Personalized Treatment, Prognosis and Genetic Testing.

Elena Fountzilas, Maria Kouspou, Alexia Eliades, Kyriaki Papadopoulou, Evangelos Bournakis, Anna Goussia, Marinos Tsiatas, Achilleas Achilleos, Kyriakos Tsangaras, Gaetan Billioud and 22 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 15 institutions in 3 countries.

Elena FountzilasDepartment of Medical Oncology, St. Lukes's Hospital, 55236 Thessaloniki, Greece.
Maria KouspouDepartment of Basic and Clinical Sciences, University of Nicosia Medical School, Nicosia 2417, Cyprus.
Alexia EliadesMedicover Genetics, Nicosia 2409, Cyprus.ORCID 0000-0001-8459-7163
Kyriaki PapadopoulouLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Evangelos BournakisOncology Unit, 2nd Department of Surgery, Aretaieio Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Anna GoussiaDepartment of Pathology, Faculty of Medicine, Ioannina University Hospital, 45500 Ioannina, Greece.
Marinos TsiatasDepartment of Oncology, Athens Medical Center, 15125 Marousi, Greece.
Achilleas AchilleosMedicover Genetics, Nicosia 2409, Cyprus.
Kyriakos TsangarasMedicover Genetics, Nicosia 2409, Cyprus.ORCID 0000-0001-7454-0454
Gaetan BillioudMedicover Genetics, Nicosia 2409, Cyprus.
Charalambos LoizidesMedicover Genetics, Nicosia 2409, Cyprus.
Christos LemesiosMedicover Genetics, Nicosia 2409, Cyprus.
Elena KypriMedicover Genetics, Nicosia 2409, Cyprus.
Marios IoannidesMedicover Genetics, Nicosia 2409, Cyprus.
George KoumbarisMedicover Genetics, Nicosia 2409, Cyprus.ORCID 0000-0002-5670-8329
Sofia LevvaMedical Oncology, Bioclinic of Thessaloniki, 54622 Thessaloniki, Greece.
Ioannis VakalopoulosFirst Department of Urology, School of Medicine, Aristotle University of Thessaloniki, "G. Gennimatas" General Hospital, 54124 Thessaloniki, Greece.ORCID 0000-0003-2187-325X
Athanasios PaliourasDepartment of Urology, Ioannina University Hospital, 45500 Ioannina, Greece.
Stavroula PervanaDepartment of Pathology, Papageorgiou Hospital, 56429 Thessaloniki, Greece.
Filippos KoinisDepartment of Medical Oncology, University General Hospital of Larissa, 41110 Larissa, Greece.
Redi BumciDepartment of Pathology, Faculty of Medicine, Ioannina University Hospital, 45500 Ioannina, Greece.
Athina ChristopoulouMedical Oncology Unit, S. Andrew Hospital, 26332 Patras, Greece.
Soultana MeditskouDepartment of Histology-Embryology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.ORCID 0000-0001-7929-9110
Amanda PsyrriSection of Medical Oncology, Department of Internal Medicine, Attikon University Hospital, Faculty of Medicine, National and Kapodistrian University of Athens School of Medicine, 12462 Athens, Greece.
Ioannis BoukovinasMedical Oncology, Bioclinic of Thessaloniki, 54622 Thessaloniki, Greece.
Anastasios VisvikisThird Department of Medical Oncology, Agii Anargiri Cancer Hospital, 14564 Athens, Greece.
Vasilios KaravasilisUniversity College London Hospitals NHS Foundation Trust, London WC1N 3BG, UK.
George K KoukoulisDepartment of Pathology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41100 Larissa, Greece.
Athanasios KotsakisDepartment of Medical Oncology, University General Hospital of Larissa, 41110 Larissa, Greece.ORCID 0000-0002-5530-6774
Dimitrios GiannakisDepartment of Urology, Faculty of Medicine, University of Ioannina, 45110 Ioannina, Greece.
George FountzilasLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.ORCID 0000-0001-8045-2186
Philippos C PatsalisDepartment of Basic and Clinical Sciences, University of Nicosia Medical School, Nicosia 2417, Cyprus.
Medicover Genetics (Cyprus)Aristotle University of Thessaloniki · GRNational and Kapodistrian University of Athens · GRUniversity Hospital of Ioannina · GRUniversity Hospital of Larissa · GRUniversity of Nicosia · CYAthens Medical Center · GREuropean University Cyprus · CYGeneral University Hospital of Patras · GRHospital Agioi Anargyroi · GRLimassol General Hospital · CYPapageorgiou General Hospital · GRUniversity College London Hospitals NHS Foundation Trust · GBUniversity of Ioannina · GRUniversity of Thessaly · GR

Funding

HeCOG TR_9/19Hellenic Society of Medical Oncology NAPfizer NA
6 · The paper itself

Abstract

The data on tumor molecular profiling of European patients with prostate cancer is limited. Our aim was to evaluate the prevalence and prognostic and predictive values of gene alterations in unselected patients with prostate cancer. The presence of gene alterations was assessed in patients with histologically confirmed prostate cancer using the ForeSENTIA

Indexed as

Precision MedicineProstatic NeoplasmsAgedGenetic TestingHumansMaleProspective StudiesBRCA2genomicsmolecular profilingmutationsoverall survivalprognosticprostate cancerTMPRSS2-ERG

Identifiers

PMID37511593
PMCPMC10380890
OpenAlexW4385223974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.